Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Share-based Compensation (2016 - 2025)

Ironwood Pharmaceuticals' Share-based Compensation history spans 16 years, with the latest figure at $3.8 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 16.27% year-over-year to $3.8 million; the TTM value through Dec 2025 reached $17.2 million, down 42.21%, while the annual FY2025 figure was $17.2 million, 42.21% down from the prior year.
  • Share-based Compensation for Q4 2025 was $3.8 million at Ironwood Pharmaceuticals, up from $3.6 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $8.7 million in Q4 2023 and bottomed at $3.6 million in Q3 2025.
  • The 5-year median for Share-based Compensation is $6.4 million (2021), against an average of $6.4 million.
  • The largest annual shift saw Share-based Compensation surged 43.84% in 2022 before it tumbled 56.63% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $6.1 million in 2021, then increased by 19.72% to $7.3 million in 2022, then rose by 19.38% to $8.7 million in 2023, then plummeted by 47.54% to $4.6 million in 2024, then fell by 16.27% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Share-based Compensation are $3.8 million (Q4 2025), $3.6 million (Q3 2025), and $4.5 million (Q2 2025).